Information Provided By: 
Fly News Breaks for December 5, 2016
GWPH
Dec 5, 2016 | 06:58 EDT
Piper Jaffray analyst Joshua Schimmer says the additional Epidiolex data from the first Dravet and Lennox-Gastaut studies presented over the weekend by GW Pharmaceuticals support approval and broad use. The totality of the data indicate an approvable drug, with secondary analyses supportive of a "meaningful benefit" with a well tolerated profile in a highly refractory patient population, Schimmer tells investors in a research note. He reiterates an Overweight rating on GW shares with a $147 price target.
News For GWPH From the Last 2 Days
There are no results for your query GWPH
